Case reports
Human immunoglobulin for diabetic amyotrophy
a promising
prospect?
A E Courtney, G V McDonnell, V H Patterson
Department of
Neurology, Royal Victoria Hospital, Grosvenor Road, Belfast BT12
6BA, UK
Correspondence to: Dr Courtney aecourtney{at}doctors.org.uk
Submitted 21 June 2000;
Accepted 2 October 2000
Diabetic neuropathies are universally recognised and cause
significant morbidity. At present improving glycaemic control is the
only recognised treatment. A man with type 2 diabetes presented with
disabling asymmetric lower limb proximal neuropathy. Rapid clinical,
functional, and electrical improvement followed treatment with
intravenous immunoglobulin. The aetiology of diabetic amyotrophy remains controversial but there is evidence for an immune mediated process and this case suggests a role for immunoglobulin in the management of this debilitating condition.
Keywords: diabetes mellitus; neuropathy; immunoglobulin
© 2001 by The Fellowship of Postgraduate Medicine
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
